Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Cassava sciences, inc. save search
Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program
Published: 2022-05-05 (Crawled : 19:00) - biospace.com/
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: -1.04%
H: 0.77%
C: -0.67%
program phase 3
Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease
Published: 2021-12-23 (Crawled : 14:00) - globenewswire.com
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: 1.26%
H: 3.94%
C: 0.14%
alzheimer disease phase 3 alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease
Published: 2021-11-18 (Crawled : 14:30) - globenewswire.com
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: 3.02%
H: 6.04%
C: -0.1%
disease alzheimer treatment phase 3 alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease
Published: 2021-10-06 (Crawled : 13:15) - biospace.com/
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: -0.51%
H: 5.45%
C: -7.68%
disease alzheimer treatment phase 3 trial refocus-alz rethink-alz alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
Published: 2021-08-24 (Crawled : 13:00) - globenewswire.com
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: 5.88%
H: 0.78%
C: -3.74%
disease alzheimer treatment fda phase 3 alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s DiseasePhase 3 Study Initiation Still Expected Fall 2021
Published: 2021-08-24 (Crawled : 13:00) - biospace.com/
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: 5.88%
H: 0.78%
C: -3.74%
disease alzheimer treatment fda phase 3 alzheimer’s alzheimer's
Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease
Published: 2021-06-21 (Crawled : 21:00) - globenewswire.com
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: -1.44%
H: 0.81%
C: -12.21%
disease alzheimer phase 3 research alzheimer’s alzheimer's disease alzheimer's
Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam -
Published: 2021-05-12 (Crawled : 13:00) - biospace.com/
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: -0.23%
H: 1.94%
C: -4.22%
grant award phase 3 research granted grant
Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease
Published: 2021-02-22 (Crawled : 14:01) - globenewswire.com
SAVA | $19.61 -7.46% -8.06% 1.3M
|
Health Technology
|
| O: 17.89%
H: 0.0%
C: -19.34%
disease alzheimer fda phase 2 positive phase 3 alzheimer’s alzheimer's disease alzheimer's
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.